Despite the beneficial effects shown in the DAPA-CKD trial with dapagliflozin on the prevention of cardiovascular and renal outcomes in CKD patients, regardless the presence of T2D [9], in our study, less than 4% of T2D patients from the DAPA-CKD like subpopulation were taking SGLT-2 inhibitors [50]. This evidence concerns the gene SLC5A2 and chronic kidney disease.